Virtual Histology Evaluation of Atherosclerosis Regression During Atorvastatin and Ezetimibe Administration: HEAVEN Study

Abstract

Randomized clinical study evaluating the impact of 12 months aggressive (atorvastatin 80mg + ezetimibe 10mg) and standard hypolipidemic therapy on coronary atherosclerosis examined by virtual histology. Dual lipid-lowering therapy starts atherosclerosis regression, but does not lead to significant changes in plaque composition.

Keywords

• Atherosclerosis
• Intravascular ultrasound
• Plaque
• Statins